Retatrutide Overview
Retatrutide, also known as LY3437943, is a triple receptor agonist designed to activate GIP, GLP-1, and glucagon receptors.
It has become one of the most closely studied investigational compounds in obesity and metabolic research.
Product Information
Retatrutide combines three metabolic signaling pathways. Clinical trials have demonstrated substantial body-weight reductions and improvements in metabolic measures.
Retatrutide remains an investigational compound rather than an established FDA-approved treatment.
How Does Retatrutide Work?
Retatrutide activates GIP, GLP-1, and glucagon receptors, combining appetite and glucose signaling with metabolic effects associated with glucagon activity.
Retatrutide Benefits & Effects
Promotes Weight Reduction
Clinical trials have demonstrated substantial reductions in body weight with Retatrutide.
Improves Glycemic Control
Clinical research has demonstrated improvements in blood-glucose measures.
Reduces Appetite
GIP and GLP-1 receptor activity influences appetite and satiety signaling.
Supports Metabolic Research
The triple-agonist mechanism makes Retatrutide relevant to obesity, diabetes, liver, and broader metabolic research.
Retatrutide Side Effects
Clinical trials have reported nausea, diarrhea, vomiting, constipation, decreased appetite, and other gastrointestinal effects, particularly during dose escalation.
Retatrutide Dosage
Phase 2 clinical research evaluated once-weekly Retatrutide regimens including 4 mg, 8 mg, and 12 mg maintenance doses, with different starting-dose escalation schedules.
These are clinical-trial doses, not a general recommendation for self-administration.
Where to Buy Retatrutide?
Retatrutide products are not sold by Purerawz. Purerawz provides informational content and may include affiliate links to third-party websites where products are listed.
Disclaimer: Retatrutide remains investigational. The information on Purerawz is educational only and should not be considered medical advice.
Research References:
PubMed — Retatrutide Phase 2 Trial · PubMed — Retatrutide Clinical Research
